Drug Approval | August 05, 2023
USFDA approves Merck’s ERVEBO for use in children 12 months of age and older
Merck continues progress in helping to protect people at risk of Zaire ebolavirus disease
Merck continues progress in helping to protect people at risk of Zaire ebolavirus disease
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
Luforbec® 100/6 pMDI aims to provide comprehensive support to patients and healthcare professionals
The collaboration between CARER and Wholeleaf aims to offer an integrated approach to cancer patients, combining services and products to optimize their well-being
The company has submitted marketing authorization applications for mRNA-1345 with the European Medicines Agency (EMA), Swissmedic in Switzerland, and the Therapeutic Goods Administration (TGA) in Australia
Granules India sponsored an initiative to ignite a drug-free revolution and contribute towards an empowered society
Oncodesign Services and ImaginAb sign a Preclinical License and Supply Agreement
Cullgen will have the option during the initial stages of clinical development to participate equally in the costs, profits and losses
Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets
Application being reviewed under the FDA Project Orbis framework, which enables concurrent reviews among US, Australia, Canada, Switzerland, Singapore and United Kingdom health authorities
Subscribe To Our Newsletter & Stay Updated
